Breakthrough diagnostic tool marks critical milestone in global TB detection strategy
The World Health Organization (WHO) has announced a landmark achievement in tuberculosis (TB) diagnostics, granting its first-ever prequalification to the Xpert MTB/RIF Ultra test, a development poised to significantly transform global TB detection and treatment.
A game-changing diagnostic tool
Produced by US-based molecular diagnostics company Cepheid, the Xpert MTB/RIF Ultra test represents a critical advancement in TB diagnosis. The test can detect the genetic material of tuberculosis-causing bacteria in spit samples, delivering accurate results within hours.
The timing of this prequalification is crucial. In October, WHO reported a staggering 8.2 million new tuberculosis cases worldwide in 2023—the highest number since global monitoring began in 1995. The disease claimed 1.25 million lives, potentially reclaiming its position as the world’s leading cause of death from a single infectious agent.
Why prequalification matters
WHO prequalification is more than a stamp of approval. It provides UN agencies like UNICEF and organizations such as the Gavi Vaccine Alliance a streamlined pathway to procure and distribute the test in resource-limited countries.
The disease disproportionately impacts 30 high-burden countries. Five nations—India, Indonesia, China, the Philippines, and Pakistan—account for more than half of global TB cases, with India alone representing over a quarter of all instances.
Expert perspectives
“This first prequalification of a diagnostic test for tuberculosis marks a critical milestone in WHO’s efforts to support countries in scaling up and accelerating access to high-quality TB assays,” said Yukiko Nakatani, WHO assistant director-general.
Rogerio Gaspar, WHO’s regulation and prequalification director, emphasized, “High-quality diagnostic tests are the cornerstone of effective TB care and prevention.”
Understanding tuberculosis
Tuberculosis is a preventable and curable bacterial infection primarily affecting the lungs. It spreads through airborne transmission when infected individuals cough, sneeze, or spit.
The Xpert MTB/RIF Ultra test’s prequalification represents more than a medical breakthrough. It signals a renewed global commitment to combating one of the world’s most persistent infectious diseases.
As healthcare systems worldwide continue to battle tuberculosis, this diagnostic tool offers a beacon of hope for early detection, precise treatment, and ultimately, saving lives.
